Vifor Pharma delivers strong full year results 2020 with an EBITDA of 576 million Swiss ...
(WorldNews Business)

ST GALLEN, Switzerland--(BUSINESS WIRE)--Mar 3, 2021-- Regulatory News: Vifor Pharma Group reported stable net sales and a continued strong increase in profitability in 2020, despite challenges to patient access from COVID-19 and the impact of a much stronger Swiss franc against the US dollar. FINANCIAL PERFORMANCE: CONTINUED PROFITABLE GROWTH AT CER Reported net sales of CHF 1,705.6 million, down 1.1%, up 3.7% at CERReported EBITDA of CHF 575.8 million, up 18.7% (up 29.4% at CER and 35.7% by also excluding the 2019 one-off IAS19 income)Other income increased significantly due to upfront and milestone payments from partnering activities and the disposal of non-core productsGross profit...